Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

This study is testing a new CAR-T cell therapy combined with an immune-targeting drug (tafasitamab) and chemotherapy in people with severe autoimmune diseases — specifically systemic sclerosis (scleroderma) with lung involvement or significant skin disease — that have not responded to standard treatments. **You may be eligible if...** - You have been diagnosed with systemic sclerosis (scleroderma) meeting the 2013 ACR/EULAR criteria - You have a positive ANA (antinuclear antibody) test at a meaningful level - You have either: diffuse scleroderma with significant skin involvement (mRSS ≥15), OR lung scarring confirmed by CT scan with progressive lung function decline — all within 7 years of your first non-Raynaud's symptom - Other autoimmune conditions (such as lupus or inflammatory myositis) may also be eligible — ask the study team **You may NOT be eligible if...** - Your disease has been present for more than 7 years (from first non-Raynaud's symptom) - You have other serious medical conditions, infections, or recent major organ issues - You are pregnant Talk to your doctor to see if this trial is right for you.